Biblio
2013
Russell Y Cruz, C., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., A Barrett, J., Ito, S., et al. (2013).
Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study.Blood.
Leen, A.M., Bollard, C.M., Mendizabal, A.M., Shpall, E.J., Szabolcs, P., Antin, J.H., Kapoor, N., Pai, S.-Y., Rowley, S.D., Kebriaei, P., et al. (2013).
Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood.
2014
Yang, X., Zhang, M., Ramos, C., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C.J., Gee, A.P., Heslop, H.E., et al. (2014).
Closely-related T-memory stem cells correlate with in-vivo expansion of CAR.CD19-T cells in patients and are preserved by IL-7 and IL-15.Blood.
Zhou, X., Di Stasi, A., Tey, S.-K., Krance, R.A., Martinez, C., Leung, K.S., Durett, A.G., Wu, M.-F., Liu, H., Leen, A.M., et al. (2014).
Long-term outcome and immune reconstitution after haploidentical stem cell transplant in recipients of allodepleted-T-cells expressing the inducible caspase-9 safety transgene.Blood.
2015
Sun, J., Huye, L.E., Lapteva, N., Mamonkin, M., Hiregange, M., Ballard, B., Dakhova, O., Raghavan, D., Durett, A.G., Perna, S.K., et al. (2015).
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.J Immunother Cancer
3, 5.
Zhou, X., Dotti, G., Krance, R.A., Martinez, C.A., Naik, S., Kamble, R.T., Durett, A.G., Dakhova, O., Savoldo, B., Di Stasi, A., et al. (2015).
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.Blood.
Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R.J., DeBruijn, J., Dominici, M., Fibbe, W.E., Gee, A.P., Gimble, J.M., et al. (2015).
International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.Cytotherapy.
]